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Abstract  
The genetic causes of malformations of cortical development (MCD) remain largely unknown. Here we report 
the discovery of multiple disease-causing missense mutations in TUBG1, DYNC1H1 and KIF2A, as well as a 
single germline mosaic mutation in KIF5C. We find a frequent recurrence of mutations in DYNC1H1, 
implying that this gene is a major locus implicated in unexplained MCD. The mutations in KIF5C, KIF2A and 
DYNC1H1 drastically affect ATP hydrolysis, productive protein folding or microtubule binding, while 
suppression of Tubg1 expression in vivo interferes with proper neuronal migration and expression of Tubg1 
mutations in S. cerevisiae results in disruption of normal microtubule behaviour. Our data reinforce the 
importance of centrosome- and microtubule-related proteins in cortical development and strongly suggest that 
microtubule-dependent mitotic and post-mitotic processes are major contributors to the pathogenesis of MCD. 
 
 3
Introduction  
The formation of the complex architecture of the mammalian brain requires coordinated timing of 
proliferation, migration and layering, as well as differentiation of distinct neuronal populations1,2. Significant 
insights into these developmental processes have emerged through genetic and neurobiological investigations 
of the mechanisms underlying disorders of cortical development. These disorders include 
lissencephaly/pachygyria (LIS), polymicrogyria (PMG) and microcephaly3-7. Many are associated with severe 
intellectual disability and epilepsy, and have traditionally been classified based on which biological process 
(proliferation, migration and cortical organization) is likely to be affected5.  
 
Genetic studies in humans and mice have identified a spectrum of mutations in genes involved in an array of 
crucial processes that often disrupt the development of the cerebral cortex and can lead to severe cortical 
malformations. Aside from genes such as ARX and WDR62 (reviewed in
5
), the predominant importance of 
genes encoding cytoskeletal proteins has become evident. For example, mutations in DCX and LIS1, both of 
which encode proteins involved in microtubule homeostasis, are associated with a large spectrum of neuronal 
migration disorders (reviewed in3). More recently, new syndromes have been described that are associated 
with mutations in Į- or ȕ-tubulin encoding genes such as TUBA1A, TUBB2B, TUBB3 and TUBB5. These 
tubulin-related cortical dysgeneses are thought to involve a combination of abnormal neuronal proliferation, 
migration, differentiation and axonal guidance8-10. The vanishing boundaries between disorders of neuronal 
migration, cortical organization and proliferation have been highlighted by the recent identification of 
mutations in WDR62 and its implication in a large spectrum of malformations that includes pachygyria, 
lissencephaly, PMG, schizencephaly, hippocampal and cerebellar abnormalities11,12. These findings, together 
with genetic and functional data, support the hypothesis that MCD-related genes are involved at multiple 
developmental stages, and that proliferation and migration are genetically and functionally interdependent.  
 
Sporadic unexplained cases of MCD are by far the most common, and identification of causative mutations 
remains a challenging task, not least because many result from de novo mutations (reviewed in13). To extend 
the spectrum of genes involved in MCD, we used an exome sequencing approach and focused on variations in 
candidate genes encoding centrosomal and microtubule-related proteins.  
 4
 
Results 
Subgroups of patients with MCD analysed by whole exome sequencing 
We selected 16 patients with either lissencephaly/pachygyria (6 patients) or polymicrogyria (10 patients) 
associated with one of the following features: microcephaly (head circumferences more than 2-3 SD below the 
mean for age), dysgenesis of the cerebellum, brainstem or basal ganglia or agenesis/dysgenesis of the corpus 
callosum (Supplementary Table 1). Supplementary Figure 1 highlights the overall experimental workflow for 
detecting and prioritizing sequence variants and validation of the MCD-related genes detailed below. All 
families had a single affected member (sporadic cases), except one in which MCD was diagnosed in four 
individuals (P20, Fig. 1a). For all patients, mutations in known MCD genes (LIS1, DCX, TUBA1A, TUBB2B, 
TUBB3 and GPR56) and pathogenic CNVs had been previously excluded.  
 
We applied whole-exome sequencing methodology and, in line with previous studies14,15, identified around 
21,500 variations affecting essential splicing site and coding regions for each patient. After application of 
variant filtering using available genomic databases (dbSNP, 1k genome, EVS and a local Paris Descartes 
Bioinformatics platform database) and exclusion of all variants found with a frequency greater than 1%, an 
average of 390 variants per patient was identified (Supplementary Table 2).  
 
A KIF5C germline mosaic mutation 
 
At first glance, in family P20 (Fig. 1a) containing 4 affected boys with severe MCD and microcephaly, the 
apparent transmission of the recurrent phenotype through the mother suggests the segregation in this family of 
an X-linked disorder. However, we found no linkage between the disease and a large set of X-linked markers 
(Supplementary Fig. 2a and 2b). Exclusion of the X chromosome and the unlikely autosomal recessive 
inheritance of the disorder (because of its occurrence even when the progenitor father was different) led us to 
consider a mosaic germline mutation in the mother. We therefore performed whole exome sequencing (using 
DNA from patient III-1, Fig. 1a) and genome-wide SNP genotyping using high-density microarray (see 
Materials and Methods) of affected members and their mother to identify shared segments transmitted by the 
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mother (Supplementary Table 3). Among the shared genomic regions, we found a region of 44 Mb on 
chromosome 2 (Supplementary Fig. 2c and 2d) which harbours a missense variant (c.710A>T, p.E237V) in 
the kinesin 5C gene (KIF5C) (Table 1). We tested the segregation of this variation in the family and found it 
to be present in all affected individuals, but absent in the mother’s DNA (derived from blood) and in the 
healthy son (Fig. 2b; see also Supplementary Fig. 2d and 2e). Also, in the case of the foetus corresponding to 
the most recent medical abortion, expression of KIF5C alleles was tested by RT-PCR using total RNA 
extracted from brain and lung; we found that both alleles were expressed to the same extent (see 
Supplementary Fig. 3a). Taken together, these data are consistent with a KIF5C germline mosaic mutation as 
the likely cause of the disease phenotype in the P20 family.  
 
KIF5C encodes a member of the kinesin superfamily of proteins, most of which are ATP-dependent molecular 
motors involved in intracellular transport along microtubules
16
. The p.E237V mutation is located in the 
microtubule-interacting domain (Fig 1b), and 3D modelling shows a surface location of this residue within the 
motor domain (Fig. 1c). The mutation might be expected to affect conformational changes of the switch II 
loop, which is required for microtubule-dependent activation of the motor16.  
 
To assess the consequences of the mutation on KIF5C function, we expressed and purified the motor domains 
of both wild type and mutant as recombinant proteins in E. coli (Supplementary Fig. 3b). The mutant protein 
behaved as a native species upon gel filtration (Supplementary Fig. 3c), eliminating the possibility that the 
mutation might result in a completely misfolded or aggregated protein. We first compared the ability of the 
wild type and mutant proteins to bind to microtubules, and found no significant difference (Fig. 1d). However, 
when we measured the ability of each KIF to hydrolyse ATP in a microtubule-dependent assay, we found a 
complete absence of measurable hydrolysis in the case of the mutant protein (Fig. 1e). This finding is 
consistent with the location of the mutated residue in the crystal structure, as well as with the deleterious 
effect of the mutation in the severe MCD diagnosed in P20 family (Supplementary Fig. 3d).  
 
The consequences of the p.E237V mutation were also tested in vivo. We expressed wild type and mutant 
KIF5C proteins by transfection in COS-7 cells, and compared their distribution and localization by double 
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label immunofluorescence. As previously reported17, we found a diffuse cytoplasmic distribution of wild type 
KIF5C with an enrichment, as fluorescent puncta, along microtubules and in cortical regions of the cell (Fig. 
1f and Supplementary Fig. 3e). In contrast, we found that mutant KIF5C heavily co-localises with and 
decorates microtubules throughout the cell, but does not appear as puncta or accumulate in cortical clusters 
(Fig. 1f and Supplementary Fig. 3e). This result is consistent with the loss of ATPase activity shown by the in 
vitro assay and is also in agreement with earlier work concerning a non-motile mutant Kif5c (p.T93N) that 
binds to microtubules but inhibits ATP hydrolysis18. In the case of the mutation identified in this family, both 
KIF5C alleles are expressed. In common with most kinesins, KIF5C functions as a tetramer consisting of two 
heavy chains and two light chains. It is therefore possible that the mutant KIF5C could titrate out the wild type 
isoform and act via a dominant negative effect. 
 
Mutations in KIF2A   
The identification of a KIF5C mutation prompted us to screen this gene in a cohort of 162 patients affected by 
various MCD (see Material and Methods), and analyse all other variations in kinesin genes revealed by WES 
and not reported in databases. Among 15 heterozygous variations, we found a single de novo missense change 
in KIF2A (c.961C>G, p.H321D) in a female patient (P462, Table 1) with frontal band heterotopia and 
posterior predominant pachygyria, severe congenital microcephaly and neonatal onset seizures (Fig. 2a and 
2b, Table 1, Supplementary Table 1 and Supplementary Table 4). We subsequently screened the KIF2A gene 
(coding exons and their flanking sequences) in the same cohort of patients and identified a second de novo 
KIF2A missense variation, c.950G>A, p.S317N (P147: Table 1 and Fig. 2a and 2b) in a girl affected by 
congenital microcephaly and posterior predominant agyria/pachygyria (Fig. 2a and Supplementary table 4).  
 
KIF2A is a member of the M-kinesins (kinesin-13 family) in which the motor domain is located in the middle 
of the protein (Fig. 2b). Rather than a direct involvement in microtubule-based motility, KIF2A functions by 
driving the ATP-dependent depolymerization of microtubules19. In addition to a potential deleterious effect 
predicted by PolyPhen-2 and SIFT algorithms20,21 (Supplementary Table 5), inspection of the protein structure 
(PDB 2GRY, Fig. 2c) shows that both conserved residues p.S317 and p.H321 are located around the 
nucleotide binding pocket, suggesting that the ability of KIF2A mutants to bind and/or hydrolyse ATP is 
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likely to be impaired. To investigate this possibility, we expressed the wild type and mutant ATP binding 
domains (amino acids 126 – 526) in E. coli as recombinant C-terminally His6-tagged proteins. We found that 
the wild type protein was present as a conspicuous Coomassie-stained band in soluble extracts of host cells 
(Fig. 2d, panel 1, lane 1, arrowed). However, the two mutant proteins expressed in parallel soluble extracts 
were not convincingly identifiable (Fig. 2d, panel 1, lanes 2 and 3); indeed, upon affinity purification, the 
mutant KIF2A proteins were recovered at a very substantially reduced level compared to the wild type control 
(Fig. 2d, panel 4 and corresponding Western blot), appearing instead at a higher level (relative to the wild type 
control) in the insoluble fraction following host cell lysis (Fig. 2d, panel 2). These data imply that the 
mutations lead to substantially reduced solubility as a result of misfolding, and therefore at a minimum result 
in a reduced yield of functional protein. We also transfected constructs engineered for the expression of these 
KIF2A mutations into COS-7 and human fibroblast cells, and analysed them by immunofluorescence. We 
consistently found that both overexpressed mutant KIF2A proteins (p.H321D and p.S317N) had an abnormal 
cellular localization (Fig. 2e and Supplementary Fig. 4a). We also examined endogenous mutant KIF2A in 
fibroblasts derived from the patient bearing the c.961C>G, p.H321D mutation and found similar results (Fig. 
2f).  
 
In view of the fact that both KIF2A alleles are expressed in patient fibroblasts (Supplementary Fig. 4b) and 
that the KIF2A molecule functions as a dimer22, our in vitro and in vivo data are consistent with a dominant-
negative effect of these mutations.  
 
Recurring mutations in DYNC1H1 and TUBG1 
We searched for the recurrence of mutations in the same gene in unrelated patients with similar phenotypes 
and identified two variations in DYNC1H1 (P122 and P398, Table 1, Supplementary Table 4 and Fig. 3) and 
two others in TUBG1 (P367 and P388, Table 1, Supplementary Table 4 and Fig. 4). The de novo mutations in 
DYNC1H1 were found in patients with complex MCD from group A (PMG group, Supplementary Table 1), 
while those in TUBG1 occurred in two patients with MCD from group B (agyria/pachygyria group, 
Supplementary Table 1). Because of the large spectrum of MCD associated with mutations in genes such as 
TUBA1A, TUBB2B and WDR6211,12,23, we analysed all variations detected in these two genes in either group 
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and identified (and confirmed) one additional de novo variation in DYNC1H1 in a patient from Group B 
(P217, Table 1 and Fig. 3a). To confirm the involvement of DYNC1H1 and TUBG1 in complex MCD, we 
screened TUBG1 and DYNC1H1 coding exons in the cohort of 162 patients with MCD. Consistent with our 
exome sequencing findings, we identified a total of 6 additional DYNC1H1 mutations (Table 1 and 
Supplementary Table 5). The finding of the same mutation (p.R3344Q) in two unrelated patients with a 
similar phenotype strongly supports the involvement of DYNC1H1 in MCD. In the case of TUBG1, the 
screening revealed one additional mutation (P478, Table 1 and Fig. 4a). Whenever possible, analysis of 
parental DNAs demonstrated the de novo occurrence of these mutations, with the exception of DYNC1H1 
p.K3241T, which we identified as a familial form of MCD (Table 1, Supplementary Fig. 5). Consistent with a 
pathogenic effect, interspecies sequence comparison and prediction showed a high degree of conservation and 
potential deleterious effect of all residues involved (Supplementary Table 5).   
 
DYNC1H1 mutations  
Among the 11 patients (8 sporadic cases, and two brothers and their mother) reported here, re-examination of 
MRI sequences identified a wide range of brain malformations (Fig. 3b, Supplementary Table 4 and 
Discussion). Because mutations in DYNC1H1 have been reported in families with dominant peripheral 
neuropathy and an axonal (type 2) form of Charcot Marie-Tooth disease (CMT2)24,25, we re-evaluated our 
patients and found clear clinical evidence of peripheral neuropathy in 3 cases. This was further confirmed in 
one patient by nerve conduction studies. 
 
DYNC1H1 (cytoplasmic dynein 1 heavy chain 1) protein is a large (>530 kDa) critical subunit of the 
cytoplasmic dynein complex26,27. The C-terminal region (AA 1846–4646) is the motor domain complex; it is 
arranged as a heptameric ring with 7 AAA domains and a stalk from which protrudes a microtubule-binding 
domain (BD)26. Interestingly, 6 out of the 8 mutations identified in patients with MCD are located in either the 
stalk domain, in AAA1 or in the linker region; the remaining two are in the tail domain (Fig. 3a). One of these 
latter mutations is located outside of the homodimerization domain, while the second (leading to a deletion of 
4 AA) is located in a region required for binding of the associated light chains DYNC1L and DYNC1LI (Fig. 
3a). Homology modelling of DYNC1H1 mutations showed that 3 are located on the surface of the 
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microtubule BD (Fig. 3c). We note that in vitro experiments have shown that a closely located mutation 
(p.R3384P) weakens microtubule binding (data from Carter and colleagues26; the residue is referenced as 
R3382).  
 
We evaluated the effect of two of our newly discovered DYNC1H1 mutations on microtubule binding. Wild 
type and mutant (p.K3336N and p.R3384Q) sequences containing the DYNC1H1 microtubule BD were fused 
with the antiparallel coiled-coil side arm contained in the native structure of seryl-tRNA synthetase27 as C-
terminally His6-tagged proteins. This chimeric arrangement fixes the alignment of the two strands of the 
coiled-coil in their native conformation such that their registry results in a relatively high microtubule binding 
affinity26. The recombinant proteins were expressed in E. coli, affinity purified and tested for their ability to 
co-sediment with taxol-polymerized microtubules through sucrose cushions. This experiment showed a 
significant reduction in microtubule binding affinity of both p.K3336N and p.R3384Q mutations compared to 
the wild type control (Fig. 3d).  
 
TUBG1 mutations 
Two patients with TUBG1 mutations (P367: c.1160T>C, p.L387P, P388: c.275A>G, p.Y92C) share a 
complex MCD combining posteriorly predominant pachygyria (or agyria) and severe microcephaly (-4SD). 
The third but less severe case (P478: c.991A>C, p.T331P) showed posterior pachygyria and laminar 
heterotopia with a thick and dysmorphic corpus callosum (Fig. 4b and Supplementary Table 4). TUBG1 is one 
of two human genes encoding γ-tubulin28 and is highly expressed in foetal brain. The protein is a structural 
component of the centrosome and associates with at least 6 other proteins to form the γ-tubulin ring complex 
(γTuRC), which functions in microtubule nucleation29. Two of the mutated residues (p.T331 and p.L387) are 
located in buried sites in two distinct α-helices (Fig. 4c); their mutation to proline residues is likely to 
destabilize these helices. One of these residues (p.T331) is located in the γ-γ interaction domain; the conserved 
mutated residue (p.Y92) is located in the vicinity of the GTP binding site (Fig. 4c) 
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The events leading to the assembly of the γTuRC are unknown. However, γ-tubulin, in common with the 
components of the α/β-tubulin heterodimer, requires facilitated folding by the cytosolic chaperonin CCT, and 
is discharged from it as a monomer30. We therefore assessed the effect of two of the γ-tubulin mutations 
(p.Y92C and p.L387P) on facilitated folding and on the structural stability of the monomer in vitro. The latter 
experiment showed that the integrity of the recombinant proteins is not significantly affected by either of the 
disease-associated mutations (Supplementary Fig. 6). On the other hand, we found a diminished yield of 
material migrating as monomeric Ȗ-tubulin in the case of p.L387P with a corresponding increase (relative to 
wild type) of radioactivity migrating as an undischarged binary complex with CCT (Fig. 4d). These data 
suggest that the chaperonin-dependent folding (and hence the yield) of monomeric γ-tubulin is compromised 
by the p.L387P mutation. The effect of the p.Y92C mutation on facilitated folding via interaction with 
chaperonin is less evident (Fig. 4d), and it therefore seems likely that this mutation (and perhaps to some 
extent the others) exert their influence via the assembly and/or functional integrity of the γTuRC. 
 
We analysed the consequences of our newly discovered disease-causing γ-tubulin mutations in vivo in two 
ways. First, we investigated the phenotype in yeast (S. cerevisiae) cells in which these mutations had been 
introduced into the conserved (although non-identical) residues in the single yeast γ-tubulin gene tub4 
(Supplementary Fig. 7a). All our mutant heterozygous and homozygous strains were viable. However, 
although we found no change in microtubule plus-end dynamics (Supplementary Table 6), tub4-W92C cells 
displayed an enhancement in the number and average maximal length of astral microtubules, as well as a 
decrease in the frequency of nucleation of new microtubules from the spindle pole body (SPD) 
(Supplementary Table 7 and Supplementary Fig. 7b). Moreover, we found abnormal mitotic features in a 
significant number of cells (tub4-W92C, 23%; tub4-V387P, 8%), consistent with incorrect nuclear positioning 
and reflecting a defect in mitotic microtubule organization (Fig. 5a and Supplementary Table 7). These data 
are consistent with both the disease-causing γ-tubulin mutations having a deleterious effect on critical aspects 
of microtubule behaviour, and with the more severe clinical phenotype associated with the p.W92C mutation. 
Second, we used in utero RNA interference to analyse the consequences of Tubg1 downregulation on cortical 
radial neuronal migration in mice. We found that brain sections of E18.5 embryos that had been 
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electroporated 4 days previously with shRNA targeting Tubg1 showed a significant fraction of RFP-positive 
cells in the subventricular zone/intermediate zone (SVZ/IZ), suggesting that Tubg1 down-regulation induced a 
significant arrest of migrating cells (Fig. 5b, shTubg1). In contrast, embryos transfected identically in utero 
with RFP alone showed strong labelling in the cortical plate (Fig. 5b, Tomato). Expression of scrambled-sh 
controls had no effect on migration (Fig. 5b, Scramble), while shRNAi-induced neuronal migration defects 
were significantly rescued by overexpression of a wild type human TUBG1 cDNA (Fig. 5b, Rescue)). 
Quantification of these effects is shown in Figure 5c. We repeated these in utero RNAi experiments using a 
second shRNA targeting the coding sequence, and found that it also affected neuronal radial migration, 
although the positions of misplaced cells appeared more disperse than with the first shRNA (data not shown). 
This observation is likely to be attributable to the fact that down-regulation of Tubg1 expression using the first 
shRNA is more efficient than in the case of the second shRNA (data not shown).  We conclude that TUBG1 
plays a critical role in neuronal migration during corticogenesis. 
 
Discussion  
Among 16 patients analysed by WES, mutations in 4 genes, KIF5C, KIF2A, DYNC1H1 and TUBG1, encoding 
proteins that interact with microtubules were identified in a subset of 7 patients. The remaining 9 patients 
include (i) 4 in whom all tested variants were inherited from one of the healthy parents, and (ii) 5 with de novo 
events predicted to alter protein functions but with no clear link to microtubules (Supplementary Table 8). 
Further screening and re-evaluation of MRI data showed that mutations inKIF5C, KIF2A, DYNC1H1 and 
TUBG1, are involved in a wide range of cortical and gyral pattern abnormalities associated with 
microcephaly, callosal, cerebellum, or brainstem dysgenesis (summarized in Supplementary table 4). First, in 
the familial form of severe MCD, P20 (Fig. 1) described here, we obtained convincing evidence for the 
presence of a maternal mosaic germline mutation in KIF5C that is responsible for the recurrence of the disease 
in four male patients. There is now a wide range of disorders for which the occurrence of parental germline 
mosaicism has been reported31. Indeed, with the recent application of DNA sequencing to whole genomes and 
whole exomes, the frequency of somatic and germline mosaicism may turn out to be higher than is currently 
appreciated. Our results highlight both the contribution of germline mosaic mutational events in families with 
recurrent genetic disorders and the power of whole exome sequencing to resolve these situations. For KIF5C, 
 12
we note that a recent report documented a de novo mutation in a sporadic patient with severe ID and 
microcephaly for whom MRI data were not available32. Second, patients with mutations in KIF2A and TUBG1 
share microcephaly and a cortical gyration pattern that more severely affects the posterior cortex. This 
gyration pattern is reminiscent of the LIS-1 related cortical gyration pattern33. Third, mutations in DYNC1H1 
are the cause of a wide spectrum of cortical malformations characterized mainly by posterior pachygyria 
(8/11, Supplementary Table 4). Some patients with mutations in DYNC1H1 had evidence of additional 
abnormalities including microcephaly, nodular heterotopia, hypoplasia of the corpus callosum and dysmorphy 
of the basal ganglia, as well as evidence of peripheral neuropathy (3/11). However, the most striking finding is 
the concomitant presence in two patients of both pachygyria and PMG patterns (Supplementary Table 4, P122 
and P217 and Fig. 3), traditionally regarded as distinct entities. This association has also been reported in 
WDR62-related disorders
11
 that include patients with microcephaly, PMG and schizenccephaly.  
 
Interestingly, missense mutations in DYNC1H1 have been primarily associated with neuropathy: an axonal 
dominant form of Charcot-Marie-Tooth disease (CMT2)25, and a dominant form of spinal muscular 
atrophy24,34. More recently, Willemsen and colleagues reported de novo missense mutations in DYNC1H1 in 
two patients with intellectual disability and signs of cortical malformations32,35. Taken together, these data 
indicate that heterozygous missense mutations in DYNC1H1 underlie a broad phenotypic spectrum extending 
from peripheral neuropathies to cerebral malformations. However, DYNC1H1 is emerging as an important and 
principal locus for mutations responsible for MCD, and its screening should be recommended in unexplained 
and difficult to classify pachygyria/lissencephaly and PMG with or without microcephaly.  
 
The data reported here extend the association between microtubule-based cellular processes and proper 
cortical development8,9,36,37 to γ-tubulin and the microtubule-dependent motor proteins KIF5C, KIF2A and 
DYNC1H1. As for α- and β-tubulin isotypes (TUBA1A, TUBB2B, TUBB3 and TUBB5), all mutations 
identified so far in the genes encoding these proteins are heterozygous missense mutations. In the absence of 
loss-of-function mutations (i.e., nonsense, frameshift, splice, or genomic deletions), such mutations favour 
dominant negative effects rather than haploinsufficiency as primary molecular mechanisms that cause disease. 
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This hypothesis is further supported by our cellular data regarding the behaviour of mutant forms of KIF5C 
and KIF2A. It is nonetheless possible that haploinsufficiency could also contribute to functional defects of 
MCD-related proteins.  
 
Our phenotypic evaluation of S. cerevisiae strains harbouring disease-causing mutations in Tub4 as well as 
our in utero suppression experiments suggest that adequate expression of Tubg1 is required for normal 
microtubule behaviour and proper neuronal migration. Previous studies - including analyses of kif2a-/- and 
Kif5c-/- mice19,38- imply that sufficient expression of functional KIF5C, KIF2A and DYNC1H1 proteins is 
also required for proper cortical development. In the case of DYNC1H1, inactivation of the mouse homologue 
is embryonic lethal39, while ENU-induced mouse mutants harbouring heterozygous missense mutations in the 
tail domain (Legs at odd angles (Loa, p.F580Y) and Cramping 1 (Cra1, p.Y1055C) mainly result in early 
onset progressive neurodegenerative diseases
40
. This analysis also revealed defects in retrograde axonal 
transport40 and defects in hippocampal neocortical lamination and neuronal migration41. In line with these 
results, Shu et al., reported that in vivo RNAi-mediated down-regulation of Dync1h1 impairs neuronal 
migration and positioning in the developing neocortex42.  
 
Our data strongly suggest that the regulation of microtubule-dependent mitotic processes in progenitor cells, 
as well as the trafficking activities of the microtubule-dependent molecular motors KIF2A, KIF5C, and 
DYNC1H1 in post-mitotic neuronal cells, are collectively essential for correct neuronal development 
(Supplementary Fig. 8). In light of this conclusion, it is understandable that functional disruption of any of 
these genes can lead to devastating defects in neuronal polarization, migration and differentiation. 
 
Data accession numbers 
Human TUBG1 (NM_001070), human KIF5C (NM_004522), human DYNC1H1 (NM_001376), human 
KIF2A (NM_001098511),  mouse Tubg1 (NM_134024), human DCX (NM_181807), human LIS1 (RefSeq 
NM_000430), human ARX (NM_139058), human TUBA1A (NM_006009), human TUBB2B (NM_178012), 
human TUBB3 (NM_006086), human GPR56 (NM_201524). 
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Figure Legends 
 
Figure 1. Recurrent severe MCD resulting from a germline mosaic mutation in KIF5C and analysis of 
mutant KIF5C ATPase activity and cellular localization 
 (a) Pedigree of the P20 family with four affected male individuals exhibiting severe MCD (Supplementary 
Fig. 3d), (b) Linear schematic representation of the KIF5C showing the position of the mutation (c) 3D model 
of the rat kinesin dimer (generated by pyMol [pdb: 3kin]) showing the p.E237 residue (red) located at the 
motor domain surface. (d) microtubule binding assay of recombinant wild type and mutant KIF5C proteins. 
Upper part shows analysis of sedimented microtubules by SDS-PAGE (as loading controls); the lower part 
shows autoradiographs of the same gels. Note that the p.E237V mutation does not appreciably affect the 
protein’s ability to bind to microtubules. (e) Kinetics of microtubule-dependent ATP hydrolysis by wild type 
and mutant KIF5C proteins. The production of Pi was measured kinetically in reactions containing taxol-
stabilized microtubules, an equal amount of purified recombinant KIF5C protein, and ATP using the 
malachite green colorimetric reaction. Diamonds and crosses represent wild type and mutant (p.E237V) 
proteins, respectively. Each time point represents the average of 6 experiments, +/- S.D. Note the complete 
absence of detectable ATP hydrolysis in the case of the p.E237V mutant protein. (f) Subcellular localization 
of transfected wild type and p.E237V mutant KIF5C in COS7 cells. KIF5C immunostaining (green) reveals a 
diffuse cytoplasmic distribution of wild type KIF5C with enrichment, as fluorescent puncta, along 
microtubules and in cortical regions of the cell, while mutant KIF5C heavily co-localises with and decorates 
microtubules (identified by α-tubulin labelling, shown in red) throughout the cell, but does not appear as 
puncta or accumulate in cortical clusters. Dapi was used as a counterstain to highlight nuclei. Scale bar 20 µm. 
 
Figure 2. Mutations in KIF2A cause posterior predominant agyria/pachygyria and compromise 
productive folding and cellular localization 
(a) Brain MRIs of patients with KIF2A mutations. Representative T1-Sagittal (first line), T2-axial (second 
line) and T2-coronal (third line) MRIs performed at 5 weeks in patient P147 and at 3 weeks in patient P462. 
Patient P147 (left hand column) shows posterior predominant agyria pachygyria, with a thick cortex and a thin 
corpus callosum. Patient P462 (right hand column) has posterior predominant pachygyria with subcortical 
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band heterotopias (arrows) and a thin corpus callosum. (b-c) Linear and 3D ribbon (pdb: 2gry) representations 
of the kinesin 2A polypeptide showing the position of the two heterozygous MCD-associated mutations 
(shown in red and pink) near the nucleotide binding site (shown in orange). (d) Folding of KIF2A. Wild type 
and mutant (p.S317N, p.H321D) forms of the KIF2A nucleotide binding domain (amino acids 126 – 526) 
were expressed in E. coli as recombinant C-terminally His6-tagged proteins.  Soluble extracts of host cells, the 
insoluble (particulate) fraction, and products that either failed to bind (non-binding) or bound and eluted 
(eluted) from columns of solid phase-bound Co++ were analysed by SDS-PAGE and (in the case of the affinity 
purified material) by Western blotting with an anti-His6 antibody. Arrow identifies the recombinant KIF2A 
nucleotide binding domain. The location of molecular mass markers is shown at the left. (e-f) 
Immunofluorescence staining of KIF2A (green) and α-tubulin (red) in either COS7 cells transfected with WT 
or mutant (p.S317N and p.H321D) KIF2A cDNA constructs (e) or in wild type and p.H321D patient-derived 
fibroblasts (f). Note that instead of the expected diffuse punctiform cytoplasmic and nuclear distribution (as 
observed for wild type KIF2A), KIF2A mutants showed a predominant co-localization with and decoration of 
microtubules. In cells expressing high levels of mutant forms of KIF2A, the decorated microtubule-network is 
mainly in the central region of the cells and around the nucleus with a disorganized and bundled appearance of 
microtubules. The nuclear distribution is also disrupted, and in the case of both mutants, the nucleus appears 
free of KIF2A. A similar altered distribution of KIF2A is evident in patient-derived fibroblasts. Scale bar 20 
mm. 
 
Figure 3. Spectrum of MCD associated with mutations in DYNC1H1 and analysis of the ability of 
mutant DYNC1H1 to bind to microtubules 
(a) Schematic representation of DYNC1H1 protein showing the position of mutations causing MCD. (b) Brain 
MRI illustrations showing the phenotypic spectrum associated with DYNC1H1 mutations. Top line, P122: 
Axial T1-weighted images showing diffuse coarse PMG, most prominent in the perisylvian region (arrow 
head). In frontal regions, PMG has the appearance of a dysmorphic cortex (*). The sagittal T2-weighted 
section shows a dysmorphic thick corpus callosum and hypoplasic brainstem. Second line, P535: Axial T1-
weighted images showing a simplified gyral pattern on both frontal regions (arrow heads), large and 
dysmorphic basal ganglia and parieto-occipital pachygyria (asterisks). Sagittal T1 weighted image shows a 
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thick and dysmorphic corpus callosum. Third line, P398: Axial T1-weighted images showing bilateral frontal 
PMG (asterisks) with multiple small gyri giving an appearance of delicate PMG. (c) Illustration of the 
structure of the DYNC1H1 MTBD (ellipses) and the distal portion of the coiled-coil stalk of mouse 
cytoplasmic dynein as a fusion with seryl tRNA-synthetase (SRS, solid circle) from Thermus thermophilus 
(pdb: 3err). The Figure shows the surface location on the microtubuleBD of p.K3336, p.R3344 and p.R3384 
residues. (d) Effect of dynein heavy chain mutations on binding to MTs. Left panel: Coomassie stain of 
purified 35S-labeled wild type and mutant-containing seryl tRNA synthetase-DYNC1H1 MTBD fusion 
proteins analysed by SDS-PAGE.  Right panels: purified labelled recombinant proteins (as shown on the left) 
were tested for their ability to co-sediment through sucrose cushions either in the presence (+Tub) or absence 
(-Tub) of taxol-polymerized MTs. Labelled material contained in the supernatants (S) and pellets (P) was 
analyzed by SDS-PAGE. Note that in the case of the mutant proteins, the amount of label sedimenting with 
MTs is reduced to a level close to that present in control reactions done without added tubulin.  
 
Figure 4. Mutations in TUBG1 cause MCD with posterior predominant pachygyria and analysis of the 
effect of Ȗ-tubulin mutations on facilitated folding 
(a) Linear representation of the TUBG1 protein showing the localization of the GTP binding site and TUBG1 
mutations. (b) Brain MRI illustrations of patients with mutations in TUBG1. Top line: Axial T1-weighted 
images in 3 different patients (respectively, P388, first column; P478 second column, and P367, third column) 
with different TUBG1 mutations show different degrees of pachygyria, with a thick cortex, most prominent in 
parieto-occipital regions (white asterisk). In the less severe case, pachygyria is milder with an aspect of 
posterior subcortical band heterotopia (red asterisk). Second line: Sagittal T1-weighted section showing a 
dysmorphic thick corpus callosum. Note that in the 3 cases, the cerebellum and brainstems are normal. (c) 3D 
model of the TUBG1 dimer (pdb: 3Cb2) showing the localization of the three mutated residues and the bound 
GTP molecule (yellow). (d) Effect of Ȗ-tubulin mutations on facilitated folding. Sequences encoding full-
length wild type and mutant (p.Y92C, p.L387P) Ȗ-tubulin were expressed as 35S-labeled proteins in 
reticulocyte lysate and the reaction products analyzed by gel filtration on Superose 6. Fractions emerging from 
the column were subjected to SDS-PAGE and the radioactivity migrating as Ȗ-tubulin quantified using a 
phosphorimager. Note the diminished yield of material migrating as monomeric Ȗ-tubulin in the case of 
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p.L387P, with a corresponding increase (relative to wild type) of radioactivity migrating as a binary complex 
with the cytosolic chaperonin (the CCT binary complex has the same apparent mass as the largest molecular 
mass marker, thyroglobulin, indicated by the black arrowhead). Arrows mark the elution position of molecular 
mass standards (thyroglobulin [black; 670kDa], IgG [orange; 158kDa], ovalbumin [purple; 44kDa], 
myoglobin [red; 17kDa]) run under identical conditions.  
 
Figure 5: TUBG1 mutations affect mitotic figures in yeast cells and suppression of expression of Tubg1 
disrupts neuronal migration in the developing mouse neocortex  
(a) Yeast mitotic figures of γ-tubulin disease-related substitutions. At least 100 cells were examined in each 
strain after transformation with GFP-Bik1p, an α-tubulin binding protein that labels mitotic spindle and astral 
microtubules. The percentage of large budded cells with nuclei and microtubule positions were scored in the 
different strains as indicated. ***p<0.001  c2 test comparisons. (b) Validated shRNAs that suppressed Tubg1 
expression in cultured N2A cells by approximately 50-60% were co-electroporated with an RFP-encoding 
reporter construct (Tomato) into progenitors cells located in the ventricular zone (VZ) of E14.5 mouse 
neocortices. The Figure shows examination of coronal sections of mouse brains 4 days after electroporation at 
E14.5 with an RFP-encoding vector (Tomato), control shRNA (Scramble), Tubg1 shRNA or Tubg1 shRNA in 
combination with pCMV6-Tubg1 (Rescue). (c) Fluorescence intensities reflecting distribution of 
electroporated cells within the cortex were converted into gray values and measured from the VZ to the MZ. 
Bars represent the mean ± SEM of fluorescence intensities in 10 equal strata (stratum 1 corresponding to the 
VZ and stratum 10 to the MZ) dividing the cortex of independent brains (Tomato n=4, Scramble n=3, sh 
Tubg1 n=11, Rescue n=2). Note that sh Tubg1 knockdown leads to an increase in the percentage of 
transfected cells located in the SVZ/IZ (strata 3 and 4) and a significant decrease in the upper layers of the CP 
(strata 9 and 10) compared with the Scramble control. Cells transfected with sh Tubg1 and pCMV6-Tubg1 
have mainly reached the upper layers of the CP (strata 8 to 10), showing that migration disruption is a specific 
consequence of Tubg1 RNAi. Student t test : *p < 0.1, **p < 0.01 and ***p < 0.001.  Scale bar: 100µm. 
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Table 1. Summary of KIF5C, KIF2A, TUBG1 and DYNC1H1 mutations.   
Patient Gene CDNA variation Protein variation Transmission 
P20 KIF5C c.710A>T p.E237V Maternal mosaicism 
P462 KIF2A c.961C>G p.H321D De novo 
P147 KIF2A c.950G>A p.S317N De novo 
P367 TUBG1 c.1160T>C p.L387P De novo 
P388 TUBG1 c.275A>G p.Y92C De novo 
P478 TUBG1 c.991A>C p.T331P Father’s DNA unavailable 
P144 DYNC1H1 c.del1976-1987 p.del659-662 De novo 
P582 DYNC1H1 c.386A>T p.K129I De novo 
P122 DYNC1H1 c.10008G>T p.K3336N De novo 
P217 DYNC1H1 c.10151G>A p.R3384Q De novo 
P398 DYNC1H1 c.4700G>A p.R1567Q De novo 
P535 DYNC1H1 c.10031G>A p.R3344Q De novo 
360J DYNC1H1 c.5884C>T p.R1962C De novo 
346D  DYNC1H1 c.9722A>C p.K3241T Familial 
574C DYNC1H1 c.10031G>A p.R3344Q De novo 
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ONLINE Methods 
 
Patients 
Patients and parents’ blood samples were obtained according to local institutional review boardsguidelines. 
16 cases were selected with either LIS (6 patients) or PMG (10 patients) in association with at least one of 
the following features: microcephaly, dysgenesis of the cerebellum, brainstem, basal ganglia or corpus 
callosum. Patients with LIS included those with agyria, pachygyria or subcortical laminar heterotopia, and 
those with PMG included perisylvian, frontal, diffuse, and multifocal PMG. 
An additional cohort of 162 patients comprising 80 patients with PMG, 58 with LIS and 24 with 
predominant posteror pachygyria, was used to perform extensive screening of candidate genes. It included 
57 patients with microcephaly, 74 with dysgenesis or agenesis of the corpus callosum, 18 with dysmorphic 
basal ganglia, and 38 with cerebellar vermian and /or hemispheric hypoplasia or dysplasia.  
All patients’ DNAs were analyzed by CGH-microarray using the NimbleGen chip 720,000-probes (720 K) 
array (Roche-NimbleGen, Madison, WI) to exclude potential pathogenic CNVs. Metabolic screening was 
performed to exclude metabolic disorders. Likewise, screening of the coding regions of DCX (RefSeq 
NM_181807), LIS1 (RefSeq NM_000430), ARX (RefSeq NM_139058), TUBA1A (RefSeq NM_006009), 
TUBB2B (RefSeq NM_178012), TUBB3 (RefSeq NM_006086) or GPR56 (RefSeq NM_201524)43-46 was 
performed to exclude pathogenic mutations.  
Genotyping 
High-throughput microarray genotyping of approximately 262,000 SNPs was performed using one array 
(version NspI) from the Affymetrix GeneChip® Human Mapping 500K Array set (Affymetrix, Santa Clara, 
CA, USA). The recommended protocol as described in the Affymetrix manual was followed.  
Whole exome sequencing and analysis 
Library generation, exome enrichment and whole exome sequencing were performed at the French National 
Centre for Genotyping (CNG, Evry, France). Briefly, libraries were prepared from 3 µg genomic DNA was 
extracted from whole blood using an optimized SureSelect Human Exome kit (Agilent, Santa Clara, CA, 
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USA) following the manufacturer’s instructions. Captured, purified and clonally amplified libraries 
targeting the exome were then sequenced on a HiSeq 2000 (Illumina, San Diego, CA, USA) according to 
the manufacturer’s recommendations. Obtained sequence reads were aligned to the human genome (hg19) 
using BWA software15. Downstream processing was carried out with the Genome analysis toolkit 
(GATK47,48, SAMtools49 and Picard Tools (http://picard.sourceforge.net). Single-nucleotide variants and 
indels were subsequently called by the SAMtools suite (mpileup, bcftools, vcfutil). All calls with a read 
coverage 5x and a Phred-scaled SNP quality of 20 were filtered out. Substitution and variation calls were 
made with the SAMtools pipeline (mpileup). Variants were annotated with an in-house Paris Descartes 
bioinformatics platform pipeline based on the Ensembl database (release 67)50. 
Variations validation and gene screening 
After exome analysis, each selected variant was confirmed by PCR and direct sequencing using parents and 
patient’s DNA. For each patient, the complete TUBG1 and KIF5C coding sequences (respectively RefSeq 
NM_001070 and NM_004522) and splice sites, as well as exons corresponding respectively to the AAA1 
and the stalk domains of DYNC1H1 (RefSeq NM_001376), were amplified in independent PCR reactions 
from genomic DNA and sequenced using BigDye dideoxyterminator chemistry and a ABI3700 DNA 
analyzer (Applied Biosystems, Foster City, CA, USA). Primer sequences and positions, PCR conditions and 
product sizes are available upon request.  
Protein modelling 
Amino acid substitutions were plotted on solved protein structures for rat kinesin, the human KIF2A 
nucleotide binding domain, human TUBG1 and the mouse Dync1h1 stalk domain in fusion with seryl-tRNA 
synthetase from Thermus thermophilus using PyMOL software (http///www.pymol.org/). Models were built 
by homology modeling using Research Collaboratory for Structural Bioinformatics PDB codes: 3kin, 2gry, 
3Cb2 and 3err. Images in Figure 1 to Figure 4 were rendered using PyMOL. 
Cloning, expression and in vitro translation  
A plasmid containing the full-length sequence encoding KIF5C was provided by Pr F. A.Stephenson, School 
of Pharmacy, University of London. A sequence encoding the N-terminal 380 amino acids of KIF5C 
containing a C-terminal His6 tag was generated from this clone by PCR.  Sequences encoding full-length 
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human γ-tubulin were from Dr. B. R. Oakley30. A sequence encoding the DYNC1H1 MTBD was obtained by 
PCR using a human brain cDNA library (Clontech, Mountain View, CA,USA) as template and inserted into 
the seryl-tRNA synthetase 12 heptad-containing α-registry fusion construct described by Carter et al.26 
(GeneBank Accession Number FJ039866). Mutations were introduced by site-directed mutagenesis using the 
QuickChange II kit (Stratagene, Santa Clara, CA, USA). For experiments requiring expression in vitro, 
sequences were inserted into the pET23b vector (Novagen, EMD Millipore Germany) and used to drive 
expression in either rabbit reticulocyte lysate (TNT, Promega, Madison, WI, USA) containing 35S-methionine, 
or in E. coli BL21DE3 pLysS in which synthesis of endogenous E. coli proteins was suppressed by incubation 
in the presence of rifampicin51.  In bacterial expression experiments, lysis was effected 2 h post-induction with 
IPTG by two successive cycles of freezing and thawing, followed by incubation with DNAse I and 
centrifugation as previously described52. Affinity purification of His6-tagged proteins from the resulting 
supernatants was done using solid phase-bound Co++ beads using the protocol recommended by the 
manufacturer (Clontech, Mountain View, CA, USA). The purity of expressed proteins was checked by SDS-
PAGE.  In some experiments, the integrity of in vitro translated wild type and mutant forms of γ-tubulin was 
assessed by measuring its susceptibility to digestion with proteinase K as described53.  
Gel filtration analyses  
The migration properties of recombinant wild type and mutant forms of KIF5C sequences containing the 
motor domains and a portion of the stalk domain was assessed on a column (1.0 x 30cm) of Superose 6 via 
FPLC (GE, Uppsala, Sweden) run in 20 mM Na phosphate buffer, pH 7.2 containing 0.1M NaCl, 0.5 mM 
EGTA and 1 mM DTT (buffer K).  The products of in vitro TNT reactions done in rabbit reticulocyte lysate 
(10 ul) were diluted with 0.1 ml of buffer K supplemented with 20 uM GTP, and centrifuged for 15 mins at 
100,000 x g at 40C to remove all particulate material.  The resulting supernatant was applied to the Superose 
6 column equilibrated and run in buffer K containing 20 uM GTP and 5% v/v glycerol.  Radioactivity 
contained in 0.5 ml fractions were measured in 20 ul aliquots by scintillation counting, and further aliquots 
were analyzed by SDS-PAGE and autoradiography.  Radioactivity contained in the band corresponding to 
γ-tubulin was quantified using a phosphorimager. 
Measurement of rates of ATP hydrolysis  
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ATP hydrolysis by recombinant WT and p.E237V mutant KIF5C forms was measured in 20ul reactions 
containing 1.0 pmole of purified protein in 20 mM PIPES buffer, pH 6.9, 1.0 mM MgCl2, 0.5 mM ATP and 
1.0 mg (measured as total protein) of taxol-polymerized microtubules.  Reaction mixtures were incubated at 
300C. At various intervals, aliquots (2.0 ul) were withdrawn and the Pi content measured using the malachite 
green phosphomolybdate assay54. 
Microtubule binding assays  
MTs purified from bovine brain55 were depolymerized in 20 mM Pipes, pH 6.9, 1 mM MgCl2, 1 mM EGTA 
by incubation on ice and cleared by centrifugation at 60,000 x g for 10 mins. Purified 35S-labeled KIF5C (in 
the range 0.2 – 6.9 nmoles) or 35S-labeled chimeric seryl-tRNA synthetase containing the DYNC1H1 
MTBD  were added to reactions containing 2.0 mg/ml depolymerized tubulin, 1 mM GTP, 0.5 mM AMP-
PNP and 20 mM taxol and the mixtures incubated at 300C for 20 mins.  Reaction products were loaded onto 
cushions (0.25 ml) containing 1 M sucrose in 40 mM MES, pH 6.8, 0.5 mM MgCl2, 0.5 mM EGTA, 0.5 
mM GTP, 0.25 mM AMP-PNP and 10 mM taxol contained in 1.5 ml Eppendorff tubes, and centrifuged for 
15 mins at 100,000 x g at 30
0
C in a Beckman TL-100 rotor.  The protein and radioactivity content of the 
resulting MT pellets (in the case of reactions done with bacterially expressed KIF5C proteins) or pellets and 
supernatants (in the case of experiments done with in vitro translated KIF5C and dynein heavy chain 
fragments) was determined following SDS-PAGE. 
Folding of KIF2A nucleotide binding domains 
Sequences spanning the centrally located nucleotide binding domain of human KIF2A (amino acids 126 - 
526) were obtained by PCR using full-length cloned wild type (Origene, Rockville, MD, USA) or mutant-
bearing cDNAs as template, and the products inserted in-frame with C-terminal His tag into the pET 23b 
vector using the Nde I and Not I sites.  Proteins were expressed in E. coli BL21 DE3 cells following induction 
with 1.0 mM IPTG at an A600 of 1.0.  2.5 hours post induction, cells were harvested by centrifugation, washed 
by resuspension in 0.3M NaCl, 1 mM MgCl2, 0.1 mM ATP, 50 mM HEPES buffer pH 7.5, and lysed by three 
brief pulses of sonication at 00C. A particle-free supernatant was obtained after two centrifugationsat 30,000 
and 200,000 x g, at 40C.  The supernatants were applied to columns of Talon cobalt affinity beads (Clontech, 
Mountain View, CA, USA); andeluted in imidazole-containing buffer.  Samples were analyzed by 9% SDS-
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PAGE and stained with Coomassie blue.  In some cases, the gel content was transferred to nitrocellulose and 
probed with a mouse anti-His monoclonal antibody. 
Cell Culture, Transfections and Immunofluorescence 
 
PCMV6 plasmids containing either full length human KIF2A (SC117315) or KIF5C (RC218796) cDNAs 
were purchased from Origene . Mutations were introduced by site directed mutagenesis using a Quikchange II 
kit. 
Constructs were transfected into COS-7 or human fibroblasts cells using a Neon transfection system 
(Lifetechnologies, Carlsbad, CA, USA) according to the manufacturer’s instructions. Cells were then grown 
on glass coverslips in Dulbecco’s Modified Eagle’s Medium containing 10% (v/v) fetal calf serum. After 
paraformaldehyde fixation, immunostaining was performed with either a rabbit polyclonal anti-KIF2A 
(ab37005, Abcam Inc.) or an anti-KIF5C antibody (ARP54736, Avivasysbio, San Diego, CA, USA or 
ab5630, Abcam Cambridge, UK) (together with a mouse monoclonal anti-Į-tubulin antibody (DM1A, Sigma-
Aldrich, St. Louis, MO). 
Yeast strains and plasmids  
Yeast strains used in this study were Y20000 (MATa/MATĮ; his3ǻ 0/his3ǻ 0; leu2ǻ /leu2ǻ 0; met15ǻ 
0/MET15; LYS2/lys2ǻ 0; ura3ǻ 0/ura3ǻ 0), all provided by EUROSCARF. The W92C and V387P 
mutations were obtained by direct mutagenesis of the Tub4 gene carried by the plasmid pKanTUB4::LEU2, 
using the QuickchangeII kit and following the manufacturer’s instructions.  
Measurement of yeast MT dynamics in vivo 
Cells were seeded and grown overnight in SD complete media at 30°C foolowing by a reseed at 30°C to 
mid-log phase. Cells were pelleted, resuspended in SD complete media , imaged on an Axio Image MI 
(Zeiss, Germany) microscope with a 100x Plan Fluor 1.4 N.A. objective, and captured using a Coolsnap HQ 
camera (Photometrics). A typical acquisition protocol acquired five z-series fluorescent images at 0.5 mm 
axial steps and one differential interference contrast (DIC) image corresponding to the central fluorescent 
image. Time-lapse image series were acquired at 10 s intervals during 10 minutes. 
shRNA contructs 
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We conducted RNAi experiments using shRNA constructs commercially designed and provided by Origene. 
Four different 29-mer sequences cloned in the pGFP-V-RS vector and targeting mouse Tubg1 (NM_134024) 
mRNA were used to identified the most efficient shRNA construct. A CAGGS-red fluorescent protein 
containing plasmid and a HuSH 29-mer non-effective (scrambled) were used as controls. Efficiency 
experiments were conducted in N2A cells, normalized by amplification of cyclophilin A and quantified by 
quantitative PCR using the SybrGreen master mix and a LC480 LightCycler instrument (Roche, Basel, 
Switzerland) according to the manufacturer’s instructions. 
In utero electroporation 
Swiss mice (Janvier, Le Genest Saint Isle, France) were mated, maintained and used in our animal facilities 
in accordance with European Union and French legislation. Timed pregnant mice (E14.5) were anesthetized 
with isoflurane (2L/min 2/4% isoflurane; Minerve, Esternay, France). The uterine horns were exposed and a 
lateral ventricle of each embryo was injected via pulled glass capillaries and a microinjector (Picospritzer II; 
General Valve Corp) with Fast Green (2 µg/ml; Sigma) combined with the following DNA constructs: 0.5 
mg/ml pCAGGS-red fluorescent protein (mRFP) either alone or together with 2 or 3µl of shRNA construct at 
1.0 mg/ml targeting TUBG1 mRNA (or scramble, or wild type cDNA). Plasmids were further electroporated 
on the head of the embryo by discharging a 4500 mF capacitor charged to 45 V with a CUY21EDIT 
electroporator (SonidelLtd, Raheny, Dublin) in five electric pulses of 50ms at 950 ms intervals. Embryonic 
mice were electroporated at E14.5 then brains were harvested after 4 days of development (E18.5), sectioned 
in 80µm slices using a VT1000S vibratome (Leica Microsystems, Reuil Malmaison, France) and maintained 
in 0.01% Azide-PBS buffer. 
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